{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T16:16:09Z","timestamp":1753892169366,"version":"3.41.2"},"reference-count":32,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,8,19]],"date-time":"2022-08-19T00:00:00Z","timestamp":1660867200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p>The emergence of <jats:italic>Plasmodium falciparum<\/jats:italic> (<jats:italic>Pf<\/jats:italic>) parasite strains tolerant of the artemisinin component and resistant to the other drug component in artemisinin combination therapies (ACTs) used for treatment now markedly complicates malaria control. Thus, development of new combination therapies are urgently required. For the non-artemisinin component, the quinolone ester decoquinate (DQ) that possesses potent activities against blood stage <jats:italic>Pf<\/jats:italic> and acts on a distinct target, namely the <jats:italic>Pf<\/jats:italic> cytochrome <jats:italic>bc<\/jats:italic><jats:sub>1<\/jats:sub> complex, was first considered. However, DQ has poor drug properties including high lipophilicity and exceedingly poor aqueous solubility (0.06\u00a0\u03bcg\/ml), rendering it difficult to administer. Thus, DQ was chemically modified to provide the secondary amide derivative RMB005 and the quinoline <jats:italic>O<\/jats:italic>-carbamate derivatives RMB059 and RMB060. The last possesses sub-nanomolar activities against multidrug resistant blood stages of <jats:italic>Pf<\/jats:italic>, and <jats:italic>P. berghei<\/jats:italic> sporozoite liver stages. Here we present the results of ADME analyses <jats:italic>in vitro<\/jats:italic> and pharmacokinetic analyses using C57BL\/6 mice. The amide RMB005 had a maximum mean whole blood concentration of 0.49 \u00b1 0.02\u00a0\u00b5M following oral administration; however, the area under the curve (AUC), elimination half-life (t<jats:sub>1\/2<\/jats:sub>) and bioavailability (BA) were not significantly better than those of DQ. Surprisingly, the quinoline <jats:italic>O<\/jats:italic>-carbamates which can be recrystallized without decomposition were rapidly converted into DQ in human plasma and blood samples. The maximum concentrations of DQ reached after oral administration of RMB059 and RMB060 were 0.23 \u00b1 0.05 and 0.11 \u00b1 0.01\u00a0\u00b5M, the DQ elimination half-lives were 4.79 \u00b1 1.66 and 4.66 \u00b1 1.16\u00a0h, and the DQ clearance were 19.40 \u00b1 3.14 and 21.50 \u00b1 3.38 respectively. Under these assay conditions, the BA of DQ could not be calculated Overall although RMB059 and -060 are labile in physiological medium with respect to the DQ parent, the potential to apply these as prodrugs is apparent from the current data coupled with their ease of preparation.<\/jats:p>","DOI":"10.3389\/fphar.2022.957690","type":"journal-article","created":{"date-parts":[[2022,8,19]],"date-time":"2022-08-19T05:23:27Z","timestamp":1660886607000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["The evaluation of ADME and pharmacokinetic properties of decoquinate derivatives for the treatment of malaria"],"prefix":"10.3389","volume":"13","author":[{"given":"Daniel J.","family":"Watson","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lizahn","family":"Laing","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard M.","family":"Beteck","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liezl","family":"Gibhard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard K.","family":"Haynes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lubbe","family":"Wiesner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2022,8,19]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"4592","DOI":"10.1128\/AAC.49.11.4592-4597.2005","article-title":"In vitro assessment of methylene blue on chloroquine-sensitive and -resistant Plasmodium falciparum strains reveals synergistic action with artemisinins","volume":"49","author":"Akoachere","year":"2005","journal-title":"Antimicrob. Agents Chemother."},{"key":"B2","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/B978-0-12-378612-8.00246-8","article-title":"Veterinary drugs residues: Coccidiostats","volume":"3","author":"Anad\u00f3n","year":"2014","journal-title":"Encycl. Food Saf."},{"key":"B3","first-page":"1","article-title":"Safety and efficacy of Deccox\u00ae (decoquinate) for chickens for fattening","volume":"17","author":"Bampidis","year":"2019","journal-title":"EFSA J."},{"key":"B4","doi-asserted-by":"publisher","first-page":"3006","DOI":"10.1016\/j.bmcl.2016.05.024","article-title":"Straightforward conversion of decoquinate into inexpensive tractable new derivatives with significant antimalarial activities","volume":"26","author":"Beteck","year":"2016","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"B5","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1038\/s42004-018-0062-7","article-title":"Accessible and distinct decoquinate derivatives active against Mycobacterium tuberculosis and apicomplexan parasites","volume":"1","author":"Beteck","year":"2018","journal-title":"Commun. Chem."},{"key":"B6","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1007\/s11095-018-2471-9","article-title":"Formulation of natural oil nano-emulsions for the topical delivery of clofazimine, artemisone and decoquinate","volume":"35","author":"Burger","year":"2018","journal-title":"Pharm. Res."},{"key":"B7","doi-asserted-by":"publisher","first-page":"e02214","DOI":"10.1128\/AAC.02214-17","article-title":"Artemisone and artemiside are potent panreactive antimalarial agents that also synergize redox imbalance in Plasmodium falciparum transmissible gametocyte stages","volume":"62","author":"Coertzen","year":"2018","journal-title":"Antimicrob. Agents Chemother."},{"key":"B8","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.1093\/infdis\/jis184","article-title":"Drug screen targeted at Plasmodium liver stages identifies a potent multistage antimalarial drug","volume":"205","author":"Cruz","year":"2012","journal-title":"J. Infect. Dis"},{"volume-title":"Ethics in Health research: Principles, processes and structures","year":"2015","key":"B9"},{"key":"B10","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.ijpharm.2005.03.022","article-title":"Development and application of high throughput plasma stability assay for drug discovery","volume":"297","author":"Di.","year":"2005","journal-title":"Int. J. Pharm."},{"key":"B11","doi-asserted-by":"publisher","first-page":"5146","DOI":"10.1128\/AAC.02975-15","article-title":"The redox cycler plasmodione is a fast-acting antimalarial lead compound with pronounced activity against sexual and early asexual blood-stage parasites","volume":"60","author":"Ehrhardt","year":"2016","journal-title":"Antimicrob. Agents Chemother."},{"key":"B12","first-page":"1","article-title":"Opinion of the scientific panel on additives and products or substances used in animal feed on a request from the commission on the coccidiostat DECCOX in accordance with article 9G of Council directive 70\/524\/EEC","volume":"17","year":"2003","journal-title":"EFSA J."},{"key":"B13","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1248\/cpb.55.328","article-title":"Synthesis and evaluation of carbamate prodrugs of a phenolic compound","volume":"55","author":"Igarashi","year":"2007","journal-title":"Chem. Pharm. Bull."},{"key":"B14","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1007\/s40471-021-00266-5","article-title":"Antimalarial drug resistance and implications for the WHO global technical strategy","volume":"8","author":"Ippolito","year":"2021","journal-title":"Curr. Epidemiol. Rep."},{"volume-title":"The characterization of pharmacokinetic properties and evaluation of","year":"2020","author":"Laing","key":"B15"},{"key":"B16","doi-asserted-by":"publisher","first-page":"5555","DOI":"10.1128\/AAC.01183-15","article-title":"ELQ-300 prodrugs for enhanced delivery and single-dose cure of malaria","volume":"59","author":"Miley","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"B18","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1021\/cb200105d","article-title":"A chemical genomic analysis of decoquinate, a Plasmodium falciparum cytochrome b inhibitor","volume":"6","author":"Nam","year":"2011","journal-title":"ACS Chem. Biol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1124\/dmd.31.5.580","article-title":"Prediction of human clearance of twenty-nine drugs from hepatic microsomal intrinsic clearance data: An examination of in vitro half-life approach and nonspecific binding to microsomes","volume":"27","author":"Obach","year":"1999","journal-title":"Drug Metab. Dispos."},{"volume-title":"Decoquinate prodrugs","year":"2012","author":"Pogany","key":"B20"},{"key":"B21","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1080\/00034983.1970.11686683","article-title":"The antimalarial activity of some quinolone esters","volume":"64","author":"Ryley","year":"1970","journal-title":"Ann. Trop. Med. Parasitol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.2147\/DDDT.S51298","article-title":"In vitro and in vivo characterization of the antimalarial lead compound SS J-183 in Plasmodium models","volume":"7","author":"Schleiferb\u00f6ck","year":"2013","journal-title":"Drug Des. devel. Ther."},{"key":"B23","doi-asserted-by":"publisher","first-page":"2245","DOI":"10.1021\/acs.jmedchem.8b01263","article-title":"Clearance in drug design","volume":"62","author":"Smith","year":"2018","journal-title":"J. Med. Chem."},{"article-title":"South African national standard: The Care and use of animals for scientific Purposes","volume-title":"South African bureau of standards","year":"2008","key":"B24"},{"key":"B27","doi-asserted-by":"publisher","first-page":"120","DOI":"10.3389\/fphar.2019.00120","article-title":"An in vitro ADME and in vivo pharmacokinetic study of novel TB-active decoquinate derivatives","volume":"10","author":"Tanner","year":"2019","journal-title":"Front. Pharmacol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1111\/j.1365-2885.2012.01421.x","article-title":"The history of decoquinate in the control of coccidial infections in ruminants","volume":"35","author":"Taylor","year":"2012","journal-title":"J. Vet. Pharmacol. Ther."},{"key":"B29","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1016\/S0140-6736(20)30552-3","article-title":"Triple artemisinin-based combination therapies versus artemisinin-based combination therapies for uncomplicated Plasmodium falciparum malaria: a multicentre, open-label, randomised clinical trial","volume":"395","author":"van der Pluijm","year":"2020","journal-title":"Lancet"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1155\/2013\/769234","article-title":"Formulation and particle size reduction improve bioavailability of poorly water-soluble compounds with antimalarial activity","volume":"769234","author":"Wang","year":"2013","journal-title":"Malar. Res. Treat."},{"key":"B31","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.nano.2013.07.010","article-title":"Nanoparticle formulations of decoquinate increase antimalarial efficacy against liver stage Plasmodium infections in mice","volume":"10","author":"Wang","year":"2014","journal-title":"Nanomedicine"},{"key":"B32","doi-asserted-by":"publisher","first-page":"901","DOI":"10.3389\/fchem.2019.00901","article-title":"Optimal 10-aminoartemisinins with potent transmission-blocking capabilities for new artemisinin combination therapies\u2013activities against blood stage P. Falciparum including PfKI3 C580Y mutants and liver stage P. berghei parasites","volume":"7","author":"Wong","year":"2020","journal-title":"Front. Chem."},{"volume-title":"World malaria report 2021","year":"2021","key":"B33"},{"key":"B34","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/s12936-022-04042-8","article-title":"Decoquinate liposomes: highly effective clearance of Plasmodium parasites causing severe malaria","volume":"21","author":"Zeng","year":"2022","journal-title":"Malar. J."},{"key":"B35","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1016\/j.cmpb.2010.01.007","article-title":"PKSolver: An add-in program for pharmacokinetic and pharmacodynamic data analysis in Microsoft Excel","volume":"99","author":"Zhang","year":"2010","journal-title":"Comput. Methods Programs Biomed."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2022.957690\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,24]],"date-time":"2022-08-24T10:22:59Z","timestamp":1661336579000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2022.957690\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,19]]},"references-count":32,"alternative-id":["10.3389\/fphar.2022.957690"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2022.957690","relation":{},"ISSN":["1663-9812"],"issn-type":[{"type":"electronic","value":"1663-9812"}],"subject":[],"published":{"date-parts":[[2022,8,19]]},"article-number":"957690"}}